BALTIMORE and PALO ALTO, Calif., Aug. 23, 2022 /PRNewswire/ — Delfi Diagnostics, Inc., a pioneering developer of a brand new class of high-performance, accessible liquid biopsy checks for early most cancers detection and monitoring, added two new senior executives to steer its Finance and Managed Care groups. Cindy Soriano has joined as Delfi’s Vice President of Finance and Chris Cisar joined Delfi not too long ago as Vice President of Market Entry and Well being Economics.
“These are important hires that may assist Delfi scale up vital, revenue-related features as we get nearer to introducing our first product,” mentioned Delfi Founder and CEO Victor Velculescu. “Cindy and Chris are exceptionally proficient leaders and I’m grateful to have their help and experience as we proceed to construct Delfi’s future.”
Cindy has over 15 years of Finance expertise. Cindy most not too long ago served as VP of FP&A at Zogenix the place she performed a key function within the firm’s sale to UCB and put up sale integration efforts. Previous to that, she held roles of accelerating seniority over 8 years at BioMarin Prescription drugs. Earlier in her profession, Cindy labored at PwC offering assurance and advisory companies throughout a wide selection of industries.
“I’m excited to affix Delfi at a time once we can construct a finance basis that may help a commercial-stage group,” Soriano mentioned. “Now’s the proper time to place the techniques and processes in place so we are able to successfully execute on Delfi’s mission when our merchandise are in the marketplace.”
Chris has nearly 3 many years of healthcare expertise spanning diagnostics, giant biotech/pharma, and healthcare consulting. Previous to becoming a member of Delfi, Chris spent 10 years in molecular diagnostics with Myriad Genetics and Veracyte, the place he led cross purposeful groups that efficiently generated convincing medical utility proof.
“A part of what makes Delfi distinctive and interesting to payers within the U.S. and world wide, is the platform’s potential to ship very excessive performing assays at a a lot decrease price than legacy liquid biopsy applied sciences,” Cisar mentioned. “Payers are searching for methods to higher serve their members and entice new ones with out taking up escalating prices.’
About Delfi Diagnostics
Delfi is growing a brand new class of liquid biopsy checks for early detection based mostly on altered genome-wide fragmentation profiles, also referred to as “fragmentomes,” representing aberrant packaging of DNA in most cancers cells. By making use of superior machine studying algorithms, these fragment patterns are detectable at a really low sequencing price. Delfi (“DNA Evaluation of Fragments for early Interception”) is utilizing this know-how to develop extremely delicate and particular most cancers detection assays supposed for broad and cost-effective distribution and adoption.
SOURCE Delfi Diagnostics
